Description and Brand Names
Drug information provided by: IBM Micromedex
US Brand Name
Pomalidomide is used in combination with dexamethasone to treat multiple myeloma (cancer of the blood) in patients who have received at least 2 other medicines that did not work well. This medicine is used in patients with multiple myeloma that has worsened during treatment or within 60 days of the last treatment. It interferes with the growth of multiple myeloma cells, which are eventually destroyed in the body. Pomalidomide is an antineoplastic (cancer medicine).
Pomalidomide is used to treat AIDS-related Kaposi sarcoma in patients who have received highly active antiretroviral therapy (HAART) that did not work well. This medicine is also used to treat Kaposi sarcoma in patients who do not have HIV infection (HIV-negative).
This medicine is available only under a restricted distribution program called the Pomalyst® REMS (Risk Evaluation and Mitigation Strategy) program.
This product is available in the following dosage forms:
Get the latest health information from Mayo Clinic’s experts.
Sign up for free, and stay up to date on research advancements, health tips and current health topics, like COVID-19, plus expertise on managing health.
ErrorEmail field is required
ErrorInclude a valid email address
To provide you with the most relevant and helpful information, and understand which
information is beneficial, we may combine your email and website usage information with
other information we have about you. If you are a Mayo Clinic patient, this could
include protected health information. If we combine this information with your protected
health information, we will treat all of that information as protected health
information and will only use or disclose that information as set forth in our notice of
privacy practices. You may opt-out of email communications at any time by clicking on
the unsubscribe link in the e-mail.
Thank you for subscribing
Our Housecall e-newsletter will keep you up-to-date on the latest health information.
Sorry something went wrong with your subscription
Please, try again in a couple of minutes